Abstract
Biological agents targeting a specific molecule have extraordinarily fine specificity and powerful functional capabilities. By the introduction of biological therapy, management of rheumatoid arthritis has undergone a revolution and a paradigm shift. In this review, I will summarize the role in the pathogenesis of rheumatoid arthritis of the molecules targeted by biological agents. Providing evidence obtained in clinical trials and investigator-initiated clinical studies in Japan, the effectiveness and safety of biological therapy in rheumatoid arthritis are discussed. Finally, studies aiming at a personalized strategy with biological agents are listed and the future perspectives toward tailor-made medicine in the field of rheumatology are discussed.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / pharmacology
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / pathology
-
Arthritis, Rheumatoid / physiopathology
-
Biological Therapy*
-
Clinical Trials as Topic
-
Etanercept
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / pharmacology
-
Immunoglobulin G / therapeutic use
-
Molecular Targeted Therapy
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Etanercept